References
- Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26:31–41.
- Gizard E, Ford AC, Bronowicki JP, et al. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:3–15.
- Olsson R, Danielsson A, Järnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100:1319–1323.
- Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16: 1598–1619.
- Halliday JS, Djordjevic J, Lust M, et al. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn’s disease. J Crohns Colitis. 2012;6:174–181.
- Boonstra K, van Erpecum KJ, van Nieuwkerk KMJ, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2270–2276.
- Ludwig J, Barham SS, LaRusso NF, et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology. 1981;1:632–640.
- Kiesslich R, Duckworth CA, Moussata D, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut. 2012;61:1146–1153.
- Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn’s disease. Scand J Gastroenterol. 1997;32:604–610.
- Navaneethan U, Venkatesh PG, Lashner BA, et al. Severity of primary sclerosing cholangitis and its impact on the clinical outcome of Crohn’s disease. J Crohns Colitis. 2012;6:674–680.
- Saarinen S, Olerup O, Broomé U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:3195–3199.
- Weismuller TJ, Wedemeyer J, Kubicka S, et al. The challenges in primary sclerosing cholangitis–aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48:S38–S57.
- Park DH, Kim MH. Intrapancreatic common bile duct involvement of autoimmune pancreatitis: is it really IgG4-associated cholangitis? Gastroenterology. 2008;135:324–325.
- Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070–2075.
- Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3350–3359.
- Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410–2422.
- Quinton JF, Sendid B, Reumaux D, et al. Anti-saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788–791.
- Donaldson PT, Norris S. Immunogenetics in PSC. Best Pract Res Clin Gastroenterol. 2001;15:611–627.
- Ennaifer R, Elleuch N, Cheikh M, et al. Risk factors of psychological disorders in inflammatory bowel disease in a Tunisian survey. Results of a cross-sectional study. Tunis Med. 2014;92:723–726.
- Héla K, Asma OK, Ali A, et al. Clinicobiological and morphological profiles of primary sclerosing cholangitis in Tunisia. Tunis Med. 2014;92:323–328.